Nykode Therapeutics AS (VACBF)
OTC Markets OTCPK · USD · Healthcare · Biotechnology
$0.2974 (+0.00%) as of
Key statistics
- Market cap
- 116.45M
- EPS (TTM)
- -0.0600
- Dividend yield
- 0.00%
- 52-week range
- 0.1558 – 0.4542
- Beta
- 0.86
- Revenue (TTM)
- 464k
- Profit margin
- 0.00%
- Volume
- 1.00k
About Nykode Therapeutics AS
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Oslo, Norway
- Employees
- 59
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.